COHORTE DE PACIENTES EN TRATAMIENTO RENAL SUSTITUTIVO HOSPITALIZADOS POR COVID-19. MORTALIDAD Y FACTORES PRONÓSTICOS (COVID19-HD)

Study identification

• EU PAS number:
  EUPAS34813
• Study ID:
  34899
• Official title and acronym:
  COHORTE DE PACIENTES EN TRATAMIENTO RENAL SUSTITUTIVO HOSPITALIZADOS POR COVID-19. MORTALIDAD Y FACTORES PRONÓSTICOS (COVID19-HD)
• DARWIN EU® study:
  No
• Study countries:
  Spain
• Study description:
  The new SARS-CoV-2 virus pandemic started in December 2019 in Wuhan, China and has spread rapidly globally. It mainly affects the respiratory and gastrointestinal tract with a mortality that ranges between 1.4 and 8% according to published records. Prognostic factors for poor evolution include advanced age, male sex, and a history of cardiovascular disease, diabetes mellitus, chronic obstructive pulmonary disease, or cancer.The course of the disease in patients requiring renal replacement therapy is poorly understood. Given the comorbidity and advanced age of these patients, mortality could be higher than that of the general population.The main objective of this study is to describe the clinical presentation in patients on renal replacement therapy and to analyze the clinical and analytical prognostic factors in this patient population, as well as the impact of the different treatments used.
• Study status:
  Ongoing

Research institutions and networks

Institutions

Ethics Committee of the Hospital General Universitario Gregorio Marañón (CEIm HGUGM)

Study timelines

Date when funding contract was signed

Planned:15/04/2020

Actual:19/04/2020

Study start date

Planned:12/03/2020

Actual:19/04/2020

Date of final study report

Planned:30/12/2020

Sources of funding

Other

More details on funding

no funding

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Non-EU RMP only